Effect of atezolizumab combined with chemotherapy on ovarian cancer and its influence on tumor markers and short-term prognosis
Objective To observe the effect of atezolizumab combined with chemotherapy in the treatment of ovarian cancer(OC)and its influence on tumor markers and short-term prognosis.Methods A total of 100 patients with OC admitted to the Second People's Hospital of Hengshui from September 2020 to September 2022 were selected as research subjects,and were divided into chemotherapy group and atezolizumab group with 50 cases in each group according to the different treatment methods.The chemotherapy group received conventional intravenous chemotherapy,and the atezolizumab group received chemotherapy combined with atezolizumab.The short-term efficacy and occurrence of adverse reactions after 6 cycles of treatment and tumor markers[carbohydrate antigen 125(CA125),human epididymal protein 4(HE4)]before treatment and after 6 cycles of treatment were compared between the two groups,and the short-term prognosis was observed in the two groups.Results After 6 cycles of treatment,the efficacy and effective rate of treatment in atezolizumab group were higher than those in chemotherapy group(P＜0.05).During treatment,the incidence rates of adverse reactions were lower in atezolizumab group than those in chemotherapy group(P＜0.05).The CA125 and HE4 levels in both groups decreased compared with those before treatment(P＜0.05),and the levels in atezolizumab group were lower than those in chemotherapy group(P＜0.05).There was no statistical difference in the recurrence rate at 6 months after treatment between the two groups(P＞0.05),and the recurrence rate at 12 months after treatment in atezolizumab group was lower than that in chemotherapy group(P＜0.05).Conclusion Atezolizumab combined with chemotherapy has significant efficacy in the treatment of OC,and it can reduce the occurrence of adverse reactions during chemotherapy,and reduce the levels of tumor markers,which is beneficial to the short-term prognosis of patients.
NETL
NSTL
万方数据
维普
